- Home
- GOODN vs CERT Comparison
GOODN vs CERT Comparison
Compare GOODN & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOODN | CERT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Real Estate | Retail: Computer Software & Peripheral Equipment |
| Sector | Real Estate | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GOODN | CERT |
|---|---|---|
| Price | $23.15 | $9.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | N/A | ★ 2.3M |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $415,551,000.00 |
| Revenue This Year | N/A | $10.82 |
| Revenue Next Year | N/A | $6.77 |
| P/E Ratio | ★ N/A | $131.28 |
| Revenue Growth | N/A | ★ 11.47 |
| 52 Week Low | N/A | $8.03 |
| 52 Week High | N/A | $15.69 |
Technical Indicators
Market Signals| Indicator | GOODN | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 46.97 |
| Support Level | $23.26 | $8.42 |
| Resistance Level | $23.58 | $9.17 |
| Average True Range (ATR) | 0.26 | 0.39 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 52.28 | 49.00 |
Price Performance
Historical ComparisonAbout GOODN Gladstone Commercial Corporation
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.